VIVORYON THERAPEUTICS AG Inactive Instrument
Vivoryon Therapeutics AG Share Price Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
| Sales 2023 | -3.62K -3.87K -310K | Sales 2024 * | - | Capitalization | 20.85M 22.3M 1.79B |
|---|---|---|---|---|---|
| Net income 2023 | -28M -29.94M -2.4B | Net income 2024 * | -18M -19.25M -1.54B | EV / Sales 2023 | -53,497 x |
| Net cash position 2023 | 18.52M 19.81M 1.59B | Net cash position 2024 * | 19.55M 20.9M 1.67B | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1.12
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vivoryon Therapeutics AG
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 31/12/11 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | 56 | 30/08/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 31/12/06 | |
| Director/Board Member | 54 | 31/12/06 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Calendar
11/06/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
